Maoyong Fu
YOU?
Author Swipe
View article: Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma
Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma Open
Pretreatmentment Lymphocytes ≥ 1.845 × 109/L were found to have a good predictive effect on the PCR and RBCs < 4.31 × 1012/L were reflective of better tumor regression grades. Therefore, RBCs < 4.31 × 1012/L may serve as a surrogate marker…
View article: Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report
Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report Open
Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, has significantly improved the survival rates of patients with locally advanc…
View article: Arsenic trioxide enhances the inhibitory effect of lenvatinib on hepatocellular carcinoma through HMOX1-mediated ferroptosis
Arsenic trioxide enhances the inhibitory effect of lenvatinib on hepatocellular carcinoma through HMOX1-mediated ferroptosis Open
Currently, Lenvatinib, a tyrosine kinase inhibitor, is used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy remains unsatisfactory. Therefore, we investigated the effect of Lenvatinib in combination …
View article: Non-intubated vs. intubated video-assisted thoracoscopic surgery for the treatment of thoracic diseases: a systematic review and meta-analysis of propensity score-matched cohorts
Non-intubated vs. intubated video-assisted thoracoscopic surgery for the treatment of thoracic diseases: a systematic review and meta-analysis of propensity score-matched cohorts Open
Background Video-assisted thoracic surgery (VATS) is commonly conducted under general anesthesia with tracheal intubation, which can lead to intubation-related complications. Consequently, non-intubated video-assisted thoracoscopic surgery…
View article: Impact of skeletal muscle loss and sarcopenia on outcomes of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
Impact of skeletal muscle loss and sarcopenia on outcomes of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma Open
Background Sarcopenia is a systemic disorder characterized by the progressive loss of skeletal muscle mass and function; however, its impact on the treatment outcomes of patients with esophageal cancer remains inconclusive. We aimed to eva…
View article: Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials
Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials Open
Background Esophageal cancer is a leading type of cancer globally. Most patients diagnosed with esophageal cancer present at a locally advanced stage, for which the standard treatment paradigm involves a multimodal approach combining neoad…
View article: Effective surgical conversion after neoadjuvant immunochemotherapy improves clinical outcomes in borderline resectable esophageal cancer
Effective surgical conversion after neoadjuvant immunochemotherapy improves clinical outcomes in borderline resectable esophageal cancer Open
Background: Immune checkpoint inhibitors have demonstrated preliminary safety and efficacy in treating borderline resectable esophageal squamous cell carcinoma (BR-ESCC). We aimed to compare treatment and survival outcomes between patients…
View article: Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma
Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma Open
Conversion surgery after induction immunochemotherapy is a promising new strategy with a high conversion rate, inspiring R0 resection rate, significant pathological remission rate, and mild toxicity for borderline resectable esophageal squ…
View article: Safety and efficacy of thrombolytic therapy in the treatment of early pulmonary embolism after thoracic surgery
Safety and efficacy of thrombolytic therapy in the treatment of early pulmonary embolism after thoracic surgery Open
Thrombolytic therapy is safe and effective for PE early after thoracic surgery in the absence of absolute contraindications for anticoagulation and thrombolysis, and it can reduce mortality in patients.
View article: Supplementary Table 1 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 1 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 59K, Known Profile of EMP2 Upregulation in Breast Cancer.
View article: Supplementary Materials and Methods from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Materials and Methods from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 68K, Supplementary Materials and Methods.
View article: Supplementary Figures 1 and 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Figures 1 and 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 855K, Supplementary Figure 1. Anti- EMP2 IgG1 can detect EMP2 in human tissue. Supplementary Figure 2. The serum levels of the human EMP2 IgG1 was compared to those of Trastuzamab.
View article: Supplementary Table Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 55K, Legends for Supplementary Tables 1 through 5.
View article: Supplementary Materials and Methods from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Materials and Methods from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 68K, Supplementary Materials and Methods.
View article: Supplementary Tables 4 and 5 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Tables 4 and 5 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 64K, Supplementary Table 4. Evaluation of EMP2 IgG1 toxicity compared to control IgG following 7 weeks of treatment delivered systemically IP. Supplementary Table 5. Evaluation of EMP2 IgG1 toxicity compared to control IgG following …
View article: Supplementary Table 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 54K, Supplementary Table 2. Clinical Data for Invasive Breast Cancer Patients used in the TMA.
View article: Supplementary Table Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 55K, Legends for Supplementary Tables 1 through 5.
View article: Supplementary Figure Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Figure Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 37K, Legends for Supplementary Figures 1 and 2
View article: Supplementary Tables 4 and 5 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Tables 4 and 5 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 64K, Supplementary Table 4. Evaluation of EMP2 IgG1 toxicity compared to control IgG following 7 weeks of treatment delivered systemically IP. Supplementary Table 5. Evaluation of EMP2 IgG1 toxicity compared to control IgG following …
View article: Data from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Data from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
Despite significant advances in biology and medicine, the incidence and mortality due to breast cancer worldwide is still unacceptably high. Thus, there is an urgent need to discover new molecular targets. In this article, we show evidence…
View article: Supplementary Figures 1 and 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Figures 1 and 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 855K, Supplementary Figure 1. Anti- EMP2 IgG1 can detect EMP2 in human tissue. Supplementary Figure 2. The serum levels of the human EMP2 IgG1 was compared to those of Trastuzamab.
View article: Supplementary Table 1 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 1 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 59K, Known Profile of EMP2 Upregulation in Breast Cancer.
View article: Supplementary Table 3 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 3 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 51K, Supplementary Table 3. Expression levels of EMP2 in triple negative breast cancer.
View article: Data from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Data from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
Despite significant advances in biology and medicine, the incidence and mortality due to breast cancer worldwide is still unacceptably high. Thus, there is an urgent need to discover new molecular targets. In this article, we show evidence…
View article: Supplementary Table 3 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 3 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 51K, Supplementary Table 3. Expression levels of EMP2 in triple negative breast cancer.
View article: Supplementary Table 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Table 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 54K, Supplementary Table 2. Clinical Data for Invasive Breast Cancer Patients used in the TMA.
View article: Supplementary Figure Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Supplementary Figure Legend from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer Open
PDF - 37K, Legends for Supplementary Figures 1 and 2